REG - Diaceutics PLC - Diaceutics PLC - Planned CEO Transition

DiaceuticsAnnouncement

26/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230926:nRSZ5960Na&default-theme=true

RNS Number : 5960N  Diaceutics PLC  26 September 2023

Diaceutics PLC - Planned CEO Transition

 

Peter Keeling stepping back as CEO, Ryan Keeling appointed CEO Designate

 

Belfast and London, 26 September 2023 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharmaceutical industry, today
announces details of its planned CEO transition.

 

Having co-founded the Company and spent 18 years as its CEO, Peter Keeling has
informed the Board of his intention to step back as CEO of Diaceutics on 1
January 2024. He will continue to serve on the Board as an Executive Director,
to support the CEO transition. Thereafter, Peter's primary focus will be to
accelerate the corporate development of Diaceutics. This will further
strengthen Diaceutics leadership position as the primary partner for
pharmaceutical companies as they seek to commercialise the new generation of
precision therapeutics across a range of disease areas over the coming months
and years.

 

Peter Keeling co-founded Diaceutics in 2005 and has led the growth of the
Company from a niche consulting service provider to a high margin, high growth
diagnostic commercialisation platform. The Company now serves 21 of the top 30
global pharma companies, with 161 people across Europe and North America and a
network of 900 laboratories worldwide. Peter also led the Company's public
listing in 2019.

 

Ryan Keeling, current Chief Innovation Officer, has today been appointed CEO
Designate and will become CEO on 1 January 2024. Ryan joined Diaceutics in
2006 and became a member of the Board on IPO in 2019. His current
responsibilities as Chief Innovation Officer will be split between the Chief
Commercial Officer and Chief Data Officer during the transition period.

 

Ryan is an expert in the commercialisation of diagnostics and associated
technology, with over 17 years' experience in the field. He is the architect
of the Company's data capabilities and DXRX platform, leading the development
and commercialisation of the Group's technology, including its proprietary
data lake. During his tenure with Diaceutics, Ryan has underpinned the
Company's growth, holding the key roles of Chief Commercial Officer, Chief
Operating Officer and most recently, Chief Innovation Officer where he has led
the Group's product innovation, with a near term focus on the development of
DXRX.

 

Deborah Davis, Chair of Diaceutics, commented: "Peter has been instrumental in
making Diaceutics what it is today. Since co-founding the business 18 years
ago, Peter has led the evolution of our Company including our IPO in 2019. For
nearly two decades, he has been a central force behind Diaceutics' performance
and growth and it is reassuring that we will retain the benefit of his wisdom
and industry thought leadership at Board level in the future. Ryan has been a
core part of our growth and development since he joined the Company in 2006
and is an exceptionally capable leader. I look forward to continuing to work
with him as we realise the full scale of the market opportunity, helping our
pharma customers identify patients in need of therapy."

 

Peter Keeling, CEO of Diaceutics, commented: "After 18 years building and
shaping the business as CEO, I believe Diaceutics has established an important
position with our customers as a thought leader in the global precision
medicine market. My decision to hand over at this time is made easy knowing
how well the Company is now positioned for growth with the talent and
motivation of the exceptional team in the business today. Having worked
closely with Ryan for more than 17 years, I have complete confidence in him to
lead Diaceutics successfully into the future, and I look forward to supporting
him and the wider team. It has been my great privilege to work alongside so
many leaders from pharmaceutical and laboratory companies, as we built a
business which is increasing the treatment opportunities for patients every
single day. I would like to take this opportunity to thank everyone at
Diaceutics for creating the important business that we are today; and for the
support they have provided to me personally throughout these foundational
years in Diaceutics."

 

Ryan Keeling, CEO Designate, commented: "Diaceutics is a thriving, growing
and global business. I am excited to be taking on the role of CEO and look
forward to building on the success that has been created over nearly two
decades.

 

I would like to thank Peter for his leadership and support and the Board for
the confidence they have placed in me to lead our exceptional business into
the future. I am fortunate to be surrounded by a remarkable and talented team
and look forward to executing against the ambitious plans we have for the
business."

 

The Company will today announce its interim results for the six months to 30
June 2023.

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance
with the Company's obligations under Article 17 of MAR. The person responsible
for making this announcement on behalf of the Company is Nick Roberts, Chief
Financial Officer.

 

Enquiries:

 Diaceutics PLC  
 Peter Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500
 Ryan Keeling, Chief Executive Officer Designate        investorrelations@diaceutics.com
 Nick Roberts, Chief Financial Officer 

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma                                                   Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almapr.co.uk
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASESESIEDSEFU